INT39892

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.36
First Reported 1985
Last Reported 2009
Negated 1
Speculated 0
Reported most in Body
Documents 3
Total Number 5
Disease Relevance 1.70
Pain Relevance 0.93

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Serpinb1b) cytoplasm (Serpinb1b)
Serpinb1b (Mus musculus)
Pain Link Frequency Relevance Heat
narcan 4 99.68 Very High Very High Very High
antagonist 42 98.40 Very High Very High Very High
Inflammatory mediators 6 95.80 Very High Very High Very High
agonist 57 91.68 High High
corticosteroid 51 91.44 High High
tolerance 18 87.60 High High
qutenza 10 87.44 High High
opiate 2 78.00 Quite High
Inflammation 15 63.96 Quite High
cva 2 25.00 Low Low
Disease Link Frequency Relevance Heat
Bronchospasm 5 100.00 Very High Very High Very High
Occupational Lung Diseases 4 96.96 Very High Very High Very High
INFLAMMATION 21 95.40 Very High Very High Very High
Exsanguination 6 95.32 Very High Very High Very High
Asthma 170 91.20 High High
Hypersensitivity 6 88.20 High High
Disease 6 64.60 Quite High
Airway Obstruction 42 51.40 Quite High
Overweight 3 36.88 Quite Low
Dyspnea 42 19.76 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The majority of clinical studies with montelukast looked at its effect on EIB after at least two days of dosing.
Regulation (effect) of EIB
1) Confidence 0.36 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789687 Disease Relevance 0.40 Pain Relevance 0.12
Naloxone had no obvious effect on EIB or the other parameters measured in association with strenuous exercise in asthmatic patients.
Neg (no) Regulation (effect) of EIB associated with bronchospasm, narcan and occupational lung diseases
2) Confidence 0.23 Published 1985 Journal Pediatr. Pulmonol. Section Abstract Doc Link 4058956 Disease Relevance 0.79 Pain Relevance 0.29
In this category, the LTRA, montelukast, has been the drug most studied and currently is approved for the control of EIB in patients aged 15 years and older in many countries.
Regulation (control) of EIB associated with antagonist
3) Confidence 0.16 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789687 Disease Relevance 0.14 Pain Relevance 0.21
Studies with LABAs have shown a protective effect on EIB of 10–12 hours,57,62 which makes them a much better therapeutic choice in such situations.
Regulation (effect) of EIB
4) Confidence 0.16 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2789687 Disease Relevance 0 Pain Relevance 0.11
These results indicate that EIB is modulated by oxygen radicals, which inactivate NEP.
Regulation (modulated) of EIB
5) Confidence 0.09 Published 1994 Journal J. Appl. Physiol. Section Abstract Doc Link 8175562 Disease Relevance 0.37 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox